X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to improve the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity medications by leveraging Ginkgo's synthetic biology platform from discovery through new ways of manufacturing.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration April 10, 2024
Details:
Through the acquisition, Ginkgo will get access to the Modulus cell therapy platform assets, including their chimeric antigen receptor and switch receptor libraries to treat solid tumors, autoimmune, and other diseases.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Modulus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Details:
Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $331.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $406.0 million Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023
Details:
The addition of StrideBio's structure-guided AAV engineering capabilities combined with Ginkgo's already extensive assets make Ginkgo a unique one-stop shop capable of providing R&D services for gene therapy manufacturing across capsid, payload, and cell line optimization.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: StrideBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 05, 2023
Details:
Proceeds will support clinical development of the Company’s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Prokarium
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing February 09, 2023
Details:
Bactofection, the process of transferring genetic material into a mammalian cell via a bacterium, is an alternative gene delivery system that could deliver therapeutic agents to a patient in RNA-based therapy.
Lead Product(s): RNA-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Prokarium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 09, 2023
Details:
CircRNAs (circular RNA based therapy) represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts.
Lead Product(s): Circular RNA-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Esperovax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2023
Details:
Circularis platform will give Ginkgo the ability to rapidly identify context-specific promoters for cell therapy and circular RNA-based therapeutic applications, such as those that modulate gene expression in the tumor microenvironment.
Lead Product(s): Circular RNA-based Therapeutic
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Circularis Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
